Gene Editing
Overview
R&D Platforms
Manufacturing
Papers & Presentations
Our Pipeline
Our Pipeline
Ex Vivo
Therapies
In Vivo
Therapies
Our Focus
Genetic Diseases
Cancer
About Us
Company Overview
Scientific Founder
Leadership
Contact Us
Careers
Company Culture
Join Us
News
Press Releases
In the Media
简体中文
中文
Edit Code of Life,
Creating Transformative Solutions for Serious Human Diseases
Press Releases
In the Media
>
News
>
Press Releases
Press Releases
All
2023
2022
2021
2020
2019
2018
Search
03
2023-05
EdiGene to Unveil Promising Preclinical POC Data for LEAPER 2.0-based in vivo RNA Editing Therapies in NHP Model at the 26th Annual Meeting of ASGCT via Oral Presentation
LEARN MORE
18
2022-11
EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia
LEARN MORE
08
2022-11
EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies
LEARN MORE
03
2022-11
EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing Hematopoietic Stem Cell Therapy, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
LEARN MORE
03
2022-05
EdiGene to Present
getools
, a Data Analysis Software Toolkit for Advanced Analytics of DNA and RNA Editing Efficiency and Outcomes for Therapeutic Development at the ASGCT 25th Annual Meeting
LEARN MORE
13
2022-04
EdiGene Enters Research Collaboration with Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer
LEARN MORE
16
2022-03
EdiGene Obtains Worldwide License from Boston Children’s Hospital to Methods and Compositions for Increasing Fetal Hemoglobin Levels to Treat Hemoglobinopathies
LEARN MORE
11
2022-02
EdiGene Announces Publication by Company Scientific Founder in Nature Biotechnology of LEAPER™ 2.0, an Updated Version of the RNA Base Editing Technology using Engineered Circular ADAR-recruiting RNAs
LEARN MORE
09
2022-02
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies
LEARN MORE
08
2022-02
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance
Ex Vivo
Engineered Cell Therapy Programs
LEARN MORE
1
2
3
4
